GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avid Bioservices Inc (NAS:CDMO) » Definitions » COGS-to-Revenue

Avid Bioservices (Avid Bioservices) COGS-to-Revenue : 0.93 (As of Jan. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Avid Bioservices COGS-to-Revenue?

Avid Bioservices's Cost of Goods Sold for the three months ended in Jan. 2024 was $31.4 Mil. Its Revenue for the three months ended in Jan. 2024 was $33.8 Mil.

Avid Bioservices's COGS to Revenue for the three months ended in Jan. 2024 was 0.93.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Avid Bioservices's Gross Margin % for the three months ended in Jan. 2024 was 7.05%.


Avid Bioservices COGS-to-Revenue Historical Data

The historical data trend for Avid Bioservices's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avid Bioservices COGS-to-Revenue Chart

Avid Bioservices Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.87 0.93 0.69 0.69 0.79

Avid Bioservices Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.74 0.79 0.89 1.18 0.93

Avid Bioservices COGS-to-Revenue Calculation

Avid Bioservices's COGS to Revenue for the fiscal year that ended in Apr. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=117.786 / 149.266
=0.79

Avid Bioservices's COGS to Revenue for the quarter that ended in Jan. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=31.432 / 33.815
=0.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avid Bioservices  (NAS:CDMO) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Avid Bioservices's Gross Margin % for the three months ended in Jan. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 31.432 / 33.815
=7.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Avid Bioservices COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Avid Bioservices's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Avid Bioservices (Avid Bioservices) Business Description

Traded in Other Exchanges
Address
14191 Myford Road, Tustin, CA, USA, 92780
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development and high-quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.
Executives
Matthew R. Kwietniak officer: Chief Commercial Officer 14191 MYFORD ROAD, TUSTIN CA 92780
Richard A. Richieri officer: Chief Operations Officer 14191 MYFORD ROAD, TUSTIN CA 92780
Daniel Ryan Hart officer: Chief Financial Officer 2642 MICHELLE DR., SUITE 200, TUSTIN CA 62780
Mark R Ziebell officer: V.P., General Counsel 14282 FRANKLIN AVENUE, TUSTIN CA 92780
Richard B Hancock director 14282 FRANKLIN AVE., TUSTIN CA 92780
Joseph Carleone director 3883 HOWARD HUGHES PKWY, SUITE 700, LAS VEGAS NV 89169
Nicholas Stewart Green director, officer: President & CEO 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Gregory Sargen director
Esther M. Alegria director 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Mark R Bamforth director 500 KENDALL ST., CAMBRIDGE MA 02142
Jeanne Thoma director C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Joel Mccomb director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Stephen Michael Hedberg officer: Principal Fin. & Acct. Officer 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780

Avid Bioservices (Avid Bioservices) Headlines

From GuruFocus

Avid Bioservices Appoints Oksana Lukash as Vice President, People

By Value_Insider Value_Insider 11-16-2022